Robert A. Bradway has been serving as the Chief Executive Officer and President of AMGEN Inc. since 2012. Born on April 1, 1963, Bradway has built a distinguished career in the biopharmaceutical industry. He joined AMGEN in 2006 as the company's Chief Financial Officer and was later promoted to President and Chief Operating Officer in 2010 before ascending to his current role. Prior to AMGEN, Bradway worked at Morgan Stanley in London, where he was a managing director and led the firm's Global Medical Technology Group. His early career also included a stint at McKinsey & Company, where he honed his strategic consulting skills. Under Bradway's leadership, AMGEN has seen significant growth and innovation. He has been instrumental in steering the company through a period of transformation, focusing on expanding AMGEN's portfolio of innovative medicines and advancing its pipeline of new drug candidates. One of his notable achievements includes the successful acquisition of Onyx Pharmaceuticals in 2013, which bolstered AMGEN's oncology offerings. Additionally, Bradway has been a proponent of sustainable business practices, integrating environmental and social governance into AMGEN's corporate strategy. His vision for the company emphasizes patient-centric solutions and global healthcare accessibility. As CEO and President, Bradway plays a pivotal role in shaping AMGEN's strategic direction and operational execution. He is actively involved in fostering a culture of scientific excellence and operational efficiency within the organization. Bradway also engages with the broader industry, serving on several influential boards and committees, including the Biotechnology Innovation Organization and the Pharmaceutical Research and Manufacturers of America. His leadership has been recognized with numerous accolades, underscoring his impact on the biopharmaceutical sector and his commitment to advancing healthcare worldwide.